Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
narcolepsy
Biotech
Phase 2b narcolepsy win powers Takeda toward pivotal trials
Takeda's faith in the mechanism has been rewarded with a primary endpoint hit—but the program only supports progression in one form of the disease.
Nick Paul Taylor
Feb 9, 2024 6:02am
Jazz halts sleep disorder med trial over 'visual disturbances'
Nov 29, 2023 10:50am
Takeda cuts ties to cancer drug landed in $120M Turnstone deal
Jul 28, 2022 7:00am
With narcolepsy approval a year out, antsy Avadel slashes staff
Jun 30, 2022 11:04am
Avadel's shares crumble as narcolepsy drug delayed yet again
May 26, 2022 10:53am
Jazz pays $50M for rights to early-phase narcolepsy prospect
May 5, 2022 8:30am